📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer. (2022)

First Author: Howard D

Attributed to: Swansea University – Confidence in Concept 2019 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fonc.2022.1014280

PubMed Identifier: 36505806

Publication URI: http://europepmc.org/abstract/MED/36505806

Type: Journal Article/Review

Volume: 12

Parent Publication: Frontiers in oncology

ISSN: 2234-943X